Screening for Hepatocellular Carcinoma and Survival in Patients With Cirrhosis After Hepatitis C Virus Cure.

ABSTRACT:

Importance

The risk of hepatocellular carcinoma (HCC) declines over time after hepatitis C virus (HCV) cure by direct-acting antiviral (DAA) therapies. Liver society guidelines recommend continuing HCC screening for these patients, but data on screening outcomes are lacking.

Objective

To evaluate the association of HCC screening after HCV cure with overall survival.

Design, setting, and participants

This cohort study evaluated patients with HCV cirrhosis who achieved DAA-induced HCV cure in the Veterans Affairs health care system between January 2014 and December 2022. Data analysis occurred from October 2023 to January 2024.

Exposures

The percentage of time spent up to date with recommended HCC screening was calculated by year of follow-up and during the 4 yea

SUBMITTER: Mezzacappa C 

PROVIDER: S-EPMC11238019 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature